216 related articles for article (PubMed ID: 23708326)
1. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance.
Yoshiji H; Noguchi R; Namisaki T; Moriya K; Kitade M; Aihara Y; Douhara A; Yamao J; Fujimoto M; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Uejima M; Uemura M; Fukui H
Oncol Rep; 2013 Aug; 30(2):545-52. PubMed ID: 23708326
[TBL] [Abstract][Full Text] [Related]
2. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Yamazaki M; Yamao J; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Fujimoto M; Uemura M; Fukui H
Oncol Rep; 2011 Dec; 26(6):1547-53. PubMed ID: 21874260
[TBL] [Abstract][Full Text] [Related]
3. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats.
Yoshiji H; Noguchi R; Kitade M; Kaji K; Ikenaka Y; Namisaki T; Yoshii J; Yanase K; Yamazaki M; Tsujimoto T; Akahane T; Kawaratani H; Uemura M; Fukui H
J Gastroenterol; 2009; 44(5):483-91. PubMed ID: 19319465
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids.
Shimizu M; Shirakami Y; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Moriwaki H
Mol Nutr Food Res; 2014 Jan; 58(1):124-35. PubMed ID: 24273224
[TBL] [Abstract][Full Text] [Related]
5. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis.
Kawaguchi T; Shiraishi K; Ito T; Suzuki K; Koreeda C; Ohtake T; Iwasa M; Tokumoto Y; Endo R; Kawamura NH; Shiraki M; Habu D; Tsuruta S; Miwa Y; Kawaguchi A; Kakuma T; Sakai H; Kawada N; Hanai T; Takahashi S; Kato A; Onji M; Takei Y; Kohgo Y; Seki T; Tamano M; Katayama K; Mine T; Sata M; Moriwaki H; Suzuki K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1012-8.e1. PubMed ID: 24036055
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.
Yoshiji H; Noguchi R; Kaji K; Ikenaka Y; Shirai Y; Namisaki T; Kitade M; Tsujimoto T; Kawaratani H; Fukui H
J Gastroenterol; 2010 Apr; 45(4):443-50. PubMed ID: 19941011
[TBL] [Abstract][Full Text] [Related]
7. Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis.
Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Douhara A; Yamao J; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Fujimoto M; Uemura M; Fukui H
Mol Med Rep; 2012 Feb; 5(2):539-44. PubMed ID: 22089860
[TBL] [Abstract][Full Text] [Related]
8. Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis.
Cha JH; Bae SH; Kim HL; Park NR; Choi ES; Jung ES; Choi JY; Yoon SK
PLoS One; 2013; 8(11):e77899. PubMed ID: 24223741
[TBL] [Abstract][Full Text] [Related]
9. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
10. Supplementation of branched-chain amino acids maintains the serum albumin level in the course of hepatocellular carcinoma recurrence.
Kakazu E; Kondo Y; Kogure T; Ninomiya M; Kimura O; Iwata T; Morosawa T; Iwasaki T; Shimosegawa T
Tohoku J Exp Med; 2013 Aug; 230(4):191-6. PubMed ID: 23892757
[TBL] [Abstract][Full Text] [Related]
11. Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma.
Ishihara T; Iwasa M; Tanaka H; Kaito M; Ikoma J; Shibata T; Takei Y
World J Gastroenterol; 2014 Mar; 20(10):2673-80. PubMed ID: 24627603
[TBL] [Abstract][Full Text] [Related]
12. Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial.
Nojiri S; Fujiwara K; Shinkai N; Iio E; Joh T
Nutrition; 2017 Jan; 33():20-27. PubMed ID: 27908546
[TBL] [Abstract][Full Text] [Related]
13. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma.
Nishikawa H; Osaki Y; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Henmi S; Sakamoto A; Ishikawa T; Saito S; Kita R; Kimura T
World J Gastroenterol; 2012 Mar; 18(12):1379-84. PubMed ID: 22493552
[TBL] [Abstract][Full Text] [Related]
14. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation.
Nishikawa H; Osaki Y; Iguchi E; Koshikawa Y; Ako S; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Ishikawa T; Saito S; Nasu A; Kita R; Kimura T
J Clin Gastroenterol; 2013 Apr; 47(4):359-66. PubMed ID: 23090049
[TBL] [Abstract][Full Text] [Related]
15. Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios.
Tada T; Kumada T; Toyoda H; Yasuda S; Koyabu T; Nakashima M
Nutr Cancer; 2019; 71(7):1132-1141. PubMed ID: 30955354
[TBL] [Abstract][Full Text] [Related]
16. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T
J Gastroenterol Hepatol; 2015 Sep; 30(9):1412-9. PubMed ID: 25799910
[TBL] [Abstract][Full Text] [Related]
17. Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels.
Mahendran Y; Jonsson A; Have CT; Allin KH; Witte DR; Jørgensen ME; Grarup N; Pedersen O; Kilpeläinen TO; Hansen T
Diabetologia; 2017 May; 60(5):873-878. PubMed ID: 28184960
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma.
Iwasa M; Sugimoto R; Ishihara T; Sekoguchi-Fujikawa N; Yoshikawa K; Mifuji-Moroka R; Tanaka H; Kobayashi Y; Hasegawa H; Takei Y
J Nutr Sci Vitaminol (Tokyo); 2015; 61(6):433-40. PubMed ID: 26875483
[TBL] [Abstract][Full Text] [Related]
19. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery.
Br J Surg; 1997 Nov; 84(11):1525-31. PubMed ID: 9393270
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus.
Kobayashi M; Ikeda K; Arase Y; Suzuki Y; Suzuki F; Akuta N; Hosaka T; Murashima N; Saitoh S; Someya T; Tsubota A; Kumada H
J Gastroenterol; 2008; 43(1):63-70. PubMed ID: 18297438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
